PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--PREEMPT CRC™ Trial for Blood-based Test to Detect Colon Cancer Has Expanded to Enroll Patients from Anywhere in the Continental U.S. During Pandemic

Click to view original post